Richard Nowak MD, MS

Assistant Professor of Neurology; Director, Program in Clinical & Translational Neuromuscular Research; Director, Yale Myasthenia Gravis Clinic

Research Interests

Myasthenia Gravis; Guillian-Barre Syndrome (GBS); CIDP; Immune Therapies, Neuropathy; Charcot Marie Tooth Disease; ALS.

Research Summary

Dr. Nowak is focused on elucidating the immunopathologic mechanisms of myasthenia gravis, an autoimmune disorder targeting the neuromuscular junction in patients resulting in weakness. He is working toward identifing new drug targets as well as exploring the effectiveness of B cell directed therapies (e.g., rituximab).

Extensive Research Description

Selected Publications

  • Nowak RJ, DiCapua DB, Zebardast, N, Goldstein JM. Response of Patients with Refractory Myasthenia Gravis to Rituximab: A Retrospective Study. Therapeutic Advances in Neurological Disorders. 2011, Sept; 4(5): 259-266.
  • Nowak RJ, Cuny GD, Choi S, Lansbury PT, Ray SS. Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods. J Med Chem. 2010, Apr 8;53(7):2709-18.
  • Ray SS, Nowak RJ, Brown RH Jr, Lansbury PT Jr. Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc Natl Acad Sci USA. 2005, Mar 8; 102(10): 3639-44.
  • Ray SS, Nowak RJ, Strokovich K, Brown RH Jr, Walz T, Lansbury PT Jr. An Intersubunit Disulfide Bond Prevents in vitro Aggregation of a Superoxide Dismutase-1 Mutant Linked to Familial ALS. Biochemistry. 2004, May 4; 43(17):4899-4905.
  • Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry. 2003, Nov 11; 42(44):12749-60.
  • Lashuel HA, Petre B, Wall, Simon M, Nowak RJ, Walz T, Lansbury PT Jr. Alpha-Synuclein, Especially the Parkinson’s Disease-Associated Mutants, Form Pore-like Annular and Tubular Protofibrils. J. Mol. Biol. 2002, 322(5): 1089-1102.
  • Anguiano M, Nowak RJ, Lansbury PT Jr. Protofibrillar Islet Amyloid Polypeptide Permeabilizes Synthetic Vesicles by a Pore-like Mechanism that May Be Relevant to Type II Diabetes. Biochemistry. 2002, Sep 24; 41(38):11338-43.

Edit Profile